#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Sofosbuvir-based regimen for genotype 2 HCV infected patients in Taiwan: A real world experience


Autoři: Wei-Lun Tsai aff001;  Chih-Feng Wang aff001;  Jin-Shiung Cheng aff001;  Wen-Chi Chen aff001;  Ming-Jong Bair aff003;  Ching-Chu Lo aff002
Působiště autorů: Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan aff001;  School of Medicine, National Yang-Ming University, Taipei, Taiwan aff002;  Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taitung Mackay Memorial Hospital, Taitung, Taiwan aff003;  Mackay Medical College, New Taipei City, Taiwan aff004;  Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Martin De Porres Hospital, Chiayi, Taiwan aff005;  Chung-Jen junior College of Nursing, Health Sciences and Management, Chiayi, Taiwan aff006
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: https://doi.org/10.1371/journal.pone.0227424

Souhrn

Background

Sofosbuvir (SOF)-based regimens achieve excellent efficacy and safety in the treatment of chronic hepatitis C (CHC) with various genotypes. There are few real-world instances of the use of SOF-based regimens to treat genotype 2 CHC. This study determines the effectiveness and safety of SOF/Ribavirn (RBV), SOF/Daclatasvir (DCV) and SOF/DCV/RBV in the treatment of genotype 2 CHC patients in Taiwan.

Material and methods

Patients with genotype 2 CHC were treated for 12 weeks with SOF/RBV, SOF/DCV or SOF/DCV/RBV under the National Health Insurance reimbursement program in three hospitals in Taiwan. The sustained virological response at 12 weeks (SVR12) was determined. Adverse events were recorded for a safety analysis.

Results

A total of 467 genotype 2 CHC patients were enrolled from January to October 2018. One hundred and eleven patients (24%) had cirrhosis, including 10 patients (2.1%) with hepatic decompensation. Fifty-five patients (12%) had already experienced interferon-alpha/RBV treatment. Forty-two patients (9%) had a history of hepatocellular carcinoma (HCC) in the baseline. Three hundred and fifty-five patients received SOF/RBV, forty-seven patients received SOF/DCV and sixty-two patients received SOF/DCV/RBV. The SOF/DCV group featured a greater HCV viral load than the SOF/RBV or SOF/DCV/RBV groups. SVR12 was achieved in 94.6% of the SOF/RBV group, 95.7% of the SOF/DCV group and 96.8% of then SOF/DCV/RBV group (P = NS). Thirteen out of 352 patients (3.7%) in the SOF/RBV group, 1 out of 62 patients (1.6%) in the SOF/DCV/RBV group and 1 out of 47 patients (2.1%) in the SOF/DCV group developed virological failure. There are no differences in virological failure between the three groups (P = NS). Multi-variate analysis shows that history of HCC is an independent factor that is associated with the failure of treatment in the SOF/RBV group (odds ratio:4.905, 95% confidence interval (CI): 1.321–18.205, P = 0.017). Hemoglobin levels at 12 weeks are significantly lower in the SOF/RBV and the SOF/RBV/DCV group than in the SOF/DCV group (P<0.05). Serious adverse events (SAE) occurred in six patients (1.6%) in the SOF/RBV group and in one patient (1.6%) in the SOF/RBV/DCV group. No patients in the SOF/DCV group experienced SAE.

Conclusions

SOF/RBV, SOF/DCV or SOF/DCV/RBV for 12 weeks all achieve very high SVR rates and are equally effective in the treatment of genotype 2 CHC patients in the real world in Taiwan. Patients in the SOF/RBV group who have a history of HCC exhibit a lower SVR rate.

Klíčová slova:

Adverse events – anémia – Cirrhosis – Hemoglobin – Hepatitis C virus – Hepatocellular carcinoma – Liver fibrosis – Taiwan


Zdroje

1. Kao J.H.; Chen D.S. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver international. 2005, 25, 696–703. https://www.ncbi.nlm.nih.gov/pubmed/15998418 doi: 10.1111/j.1478-3231.2005.01139.x 15998418

2. Heimbach J.; Kulik L.M.; Finn R.; Sirlin C.B.; Abecassis M.; Roberts L.R.; Zhu A.; Murad M.H.; Marrero J. Aasld guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017 Jan 28. https://www.ncbi.nlm.nih.gov/pubmed/28130846 doi: 10.1002/hep.29086 28130846

3. Fattovich G.; Stroffolini T.; Zagni I.; Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004, 127, suppl 1. S35–50. https://www.ncbi.nlm.nih.gov/pubmed/15508101 doi: 10.1053/j.gastro.2004.09.014 15508101

4. Welsch C.; Zeuzem S. Will Interferon-Free Regimens Prevail? Gastroenterology. 2012, 142, 1351–1355. https://www.ncbi.nlm.nih.gov/pubmed/22537442 doi: 10.1053/j.gastro.2011.12.062 22537442

5. Schaefer, eak.; Chung R.T. Anti_Hepatitis C Virus Drugs in Development. Gastroenterology. 2012, 142, 1340–1350. https://www.ncbi.nlm.nih.gov/pubmed/22537441 doi: 10.1053/j.gastro.2012.02.015 22537441

6. AASLD-IDSA HCV Guidance Panel. Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases. 2018, 67(10), 1477–92. https://www.ncbi.nlm.nih.gov/pubmed/30215672 doi: 10.1093/cid/ciy585 30215672

7. Manns M.P.; Buti M.; Gane E.; Pawlotsky J.M.; Razavi H.; Terrault N.; et al. Hepatitis C virus infection. Nat Rev Dis Prim. 2017, 3, 17006. https://www.ncbi.nlm.nih.gov/pubmed/28252637 doi: 10.1038/nrdp.2017.6 28252637

8. Van Der Meer A.J.; Veldt B.J.; Feld J.J.; Wedemeyer H.; Dufour J.F.; Lammert F.; et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012, 308, 2584–93. https://www.ncbi.nlm.nih.gov/pubmed/23268517 doi: 10.1001/jama.2012.144878 23268517

9. Falade-Nwulia O.; Suarez-Cuervo C.; Nelson D.R.; Fried M.W.; Segal J.B.; Sulkowski M.S. Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med. 2017 May 2, 166(9), 637–648. https://www.ncbi.nlm.nih.gov/pubmed/28319996 doi: 10.7326/M16-2575 28319996

10. Cheung M.C.M.; Walker A.J.; Hudson B.E. Verma S.; McLauchlan J.; Mutimer D.J.; et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016, 65, 741–7. https://www.ncbi.nlm.nih.gov/pubmed/27388925 doi: 10.1016/j.jhep.2016.06.019 27388925

11. Jacobson I.M.; Gordon S.C.; Kowdley K.V.; et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013, 368, 1867–1877. https://www.ncbi.nlm.nih.gov/pubmed/23607593 doi: 10.1056/NEJMoa1214854 23607593

12. Zeuzem S.; Dusheiko G.M.; Salupere R.; et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014, 370, 1993–2001. https://www.ncbi.nlm.nih.gov/pubmed/24795201 doi: 10.1056/NEJMoa1316145 24795201

13. Omata M.; Nishiguchi S.; Ueno Y.; Mochizuki H.; Izumi N,; Ikeda F. et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014 Nov, 21(11), 762–8. https://www.ncbi.nlm.nih.gov/pubmed/25196837 doi: 10.1111/jvh.12312 25196837

14. Kao J.H.; Chien R.N.; Chang T.T.; Peng C.Y.; Hu T.H.; Lo G.H, et al. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int. 2016 Aug, 36(8), 1101–7. https://www.ncbi.nlm.nih.gov/pubmed/26835876 doi: 10.1111/liv.13082 26835876

15. Tacke F.; Günther R.; Buggisch P.; Klinker H.; Schober A.; John C. et al., Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials. Liver Int. 2017 Feb, 37(2), 205–211. https://www.ncbi.nlm.nih.gov/pubmed/27428297 doi: 10.1111/liv.13206 27428297

16. Akahane T.; Kurosaki M.; Itakura J.; Tsuji K.; Joko K.; Kimura H. et al. Real-world efficacy and safety of sofosbuvir + ribavirin for hepatitis C genotype 2: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. Hepatol Res. 2019 Mar, 49(3), 264–270. https://www.ncbi.nlm.nih.gov/pubmed/30171740 doi: 10.1111/hepr.13246 30171740

17. Welzel T.M.; Nelson D.R.; Morelli G.; Di Bisceglie A.; Reddy R.K.;. HCV-TARGET Study Group. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut. 2017 Oct, 66(10), 1844–1852. https://www.ncbi.nlm.nih.gov/pubmed/27418632 doi: 10.1136/gutjnl-2016-311609 27418632

18. Mangia A.; Susser S.; Piazzolla V.; Agostinacchio E.; De Stefano G.; Palmieri V. et al., Sofosbuvir and ribavirin for genotype 2 HCV infected patients with cirrhosis: A real life experience. J Hepatol. 2017 Apr, 66(4), 711–717. https://www.ncbi.nlm.nih.gov/pubmed/27965158 doi: 10.1016/j.jhep.2016.12.002 27965158

19. Kanda T1.; Nakamura M2.; Yasui S3.; Haga Y4.; Tawada A5.; Suzuki E6. Et al., Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology (Basel). 2017 May 9, 6(2), pii: E30. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485477/ doi: 10.3390/biology6020030 28486403

20. Sulkowski MS.; Gardiner DF.; Rodriguez-Torres M.; Reddy K.R.; Hassanein T.; Jacobson I, et al., Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan 16, 370(3), 211–21, doi: 10.1056/NEJMoa1306218 https://www.nejm.org/doi/full/10.1056/NEJMoa1306218 24428467

21. Zhou N.; Han Z.; Hartman-Neumann S.; DeGray B.; Ueland J.; Vellucci V.; Hernandez D.; McPhee F. Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens. J Antimicrob Chemother. 2016 Dec, 71(12), 3495–3505 https://www.ncbi.nlm.nih.gov/pubmed/27605597 doi: 10.1093/jac/dkw336 27605597

22. Mangia A.; Arleo A.; Copetti M.; Miscio M.; Piazzolla V.; Santoro R. Squillante MM The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int. 2016 Jul, 36(7), 971–6. https://www.ncbi.nlm.nih.gov/pubmed/26786792 doi: 10.1111/liv.13069 26786792

23. Wang J.H.; Changchien C.S.; Hung C.H.; Eng H.L.; Tung W.C.; Kee K.M.; et al. FibroScan and ultrasonography in the prediction of hepatic fibrosis in patients with chronic viral hepatitis. J Gastroenterol. 2009, 44, 439–46. https://www.ncbi.nlm.nih.gov/pubmed/19308312 doi: 10.1007/s00535-009-0017-y 19308312

24. Sterling R.K.; Lissen E.; Clumeck N.; Sola R.; Correa M.C.; Montaner J.; et. al. Development of a simple noninvasive index to predict significant fibrosis patients with HIV/HCV co-infection. Hepatology. 2006, 43, 1317–1325. https://www.ncbi.nlm.nih.gov/pubmed/16729309 doi: 10.1002/hep.21178 16729309

25. Bedossa P.; Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996, 24, 289–293. https://www.ncbi.nlm.nih.gov/pubmed/8690394 doi: 10.1002/hep.510240201 8690394

26. Lin D.Y.; Sheen I.S.; Chiu C.T.; Lin S.M.; Kuo Y.C.; Liaw Y.F. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound. 1993 Jun, 21(5), 303–8. https://www.ncbi.nlm.nih.gov/pubmed/8514896 doi: 10.1002/jcu.1870210502 8514896

27. Heimbach J.K.; Kulik L.M.; Finn R.S.; Sirlin C.B.; Abecassis M.M.; Roberts L.R.; et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018, 67, 358–80. https://www.ncbi.nlm.nih.gov/pubmed/28130846 doi: 10.1002/hep.29086 28130846

28. Omata M.; Cheng A.L.; Kokudo N.; Kudo M.; Lee J.M.; Jia J.; et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017, 11, 317–70. https://www.ncbi.nlm.nih.gov/pubmed/28620797 doi: 10.1007/s12072-017-9799-9 28620797

29. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018, 69, 182–236. https://www.ncbi.nlm.nih.gov/pubmed/29628281 doi: 10.1016/j.jhep.2018.03.019 29628281.

30. Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun-Al-Mahtab, et al.,. APASL consensus statements and recommendation on treatment of hepatitis C.Omata M1,2, Kanda T3, Wei L4, Yu ML5, Chuang WL6, Ibrahim A7, Lesmana CR8, Sollano J910 Hepatol Int. 2016 Sep;10(5):702–26. https://www.ncbi.nlm.nih.gov/pubmed/2713047 doi: 10.1007/s12072-016-9717-6 27130427.

31. EASL Recommendations on Treatment of Hepatitis C 2018.European Association for the Study of the Liver. J Hepatol. 2018 Aug, 69(2), 461–511. https://easl.eu/wp-content/uploads/2018/10/HepC-English-report.pdf doi: 10.1016/j.jhep.2018.03.026 29650333

32. Backus L.I.; Belperio P.S.; Shahoumian T.A.; Loomis T.P.; Mole L.A. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther. 2015, 42, 559–73. https://www.ncbi.nlm.nih.gov/pubmed/26113432 doi: 10.1111/apt.13300 26113432

33. Zeuzem S.; Dusheiko G.M.; Salupere R.; Mangia A.; Flisiak R.; Hyland R.H.; et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014, 370, 1993–2001. doi: 10.1056/NEJMoa1316145 24795201

34. Foster G.R.; Pianko S.; Brown A.; Forton D.; Nahass R.G.; George J.; et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015, 149, 1462–70. https://www.ncbi.nlm.nih.gov/pubmed/26248087 doi: 10.1053/j.gastro.2015.07.043 26248087

35. Cheng P.N.; Chiu Y.C,; Chien S.C.; Chiu H.C. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. J Formos Med Assoc. 2019 May, 118(5), 907–913. https://www.ncbi.nlm.nih.gov/pubmed/30316677 doi: 10.1016/j.jfma.2018.09.016 30316677

36. Wu S.H.; Chu C.J.; Su C.W.; Lin C.C.; Lee S.D.; Wang Y.J, et al., Daclatasvir plus sofosbuvir, with or without ribavirin, is highly effective for all kinds of genotype-2 chronic hepatitis-C infection in Taiwan. J Chin Med Assoc. 2019 in press. https://www.ncbi.nlm.nih.gov/pubmed/31356562 doi: 10.1097/JCMA.0000000000000148 31356562

37. Belperio P.S.; Shahoumian T.A.; Loomis T.P.; Mole L.A.; Backus L.I. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. J Hepatol. 2019 Jan, 70(1), 15–23. https://www.ncbi.nlm.nih.gov/pubmed/30266283 doi: 10.1016/j.jhep.2018.09.018 30266283

38. Swallow E.; Song J.; Yuan Y.; Kalsekar A.; Kelley C.; Peeples M, et al.,Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison. Clin Ther. 2016 Feb, 38(2), 404–12. https://www.ncbi.nlm.nih.gov/pubmed/26839044 doi: 10.1016/j.clinthera.2015.12.017 26839044

39. Prenner S.B.; VanWagner L.B.; Flamm S.L.; Salem R.; Lewandowski R.J.; Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017 Jun, 66(6), 1173–1181. doi: 10.1016/j.jhep.2017.01.020 Epub 2017 Feb 2. https://www.ncbi.nlm.nih.gov/pubmed/28161470 28161470

40. Beste L.A.; Green P.K.; Berry K.; Kogut M.J.; Allison S.K.; Ioannou G.N. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol. 2017 Jul, 67(1), 32–39. https://www.ncbi.nlm.nih.gov/pubmed/28267622 doi: 10.1016/j.jhep.2017.02.027 28267622

41. Yen Y.H.; et al. Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviraltreatment failure: a retrospective study with prospectively collected data. Plos one. 2019 in press. https://www.ncbi.nlm.nih.gov/pubmed/31581209 doi: 10.1371/journal.pone.0222605 31581209

42. Huang CF, Yeh ML, Huang CI, Liang PC, Lin YH, Hsieh MY, et al., Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study.BMJ Open. 2019 May 5;9(5):e026703. https://www.ncbi.nlm.nih.gov/pubmed/6501994 doi: 10.1136/bmjopen-2018-026703 31061041

43. Liu C.H.; Sun H.Y.; Liu C.J.; et al. Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients with or without human immunodeficiency virus coinfection. Aliment Pharmacol Ther. 2018, 47, 1690–8. https://www.ncbi.nlm.nih.gov/pubmed/29665069 doi: 10.1111/apt.14647 29665069


Článek vyšel v časopise

PLOS One


2020 Číslo 1
Nejčtenější tento týden
Nejčtenější v tomto čísle
Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Svět praktické medicíny 2/2025 (znalostní test z časopisu)
nový kurz

BONE ACADEMY 2025
Autoři: prof. MUDr. Pavel Horák, CSc., doc. MUDr. Ludmila Brunerová, Ph.D, doc. MUDr. Václav Vyskočil, Ph.D., prim. MUDr. Richard Pikner, Ph.D., MUDr. Olga Růžičková, MUDr. Jan Rosa, prof. MUDr. Vladimír Palička, CSc., Dr.h.c.

Cesta pacienta nejen s SMA do nervosvalového centra
Autoři: MUDr. Jana Junkerová, MUDr. Lenka Juříková

Eozinofilní zánět a remodelace
Autoři: MUDr. Lucie Heribanová

Hypertrofická kardiomyopatie: Moderní přístupy v diagnostice a léčbě
Autoři: doc. MUDr. David Zemánek, Ph.D., MUDr. Anna Chaloupka, Ph.D.

Všechny kurzy
Kurzy Podcasty Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Zadejte e-mailovou adresu, se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se

#ADS_BOTTOM_SCRIPTS#